Greg Harrison
Stock Analyst at B of A Securities
(2.45)
# 1,694
Out of 4,479 analysts
25
Total ratings
47.37%
Success rate
1.54%
Average return
Main Sectors:
Top Industries:
16 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Buy | $13 → $15 | $11.83 | +26.80% | 2 | Dec 21, 2023 | |
| BEAM Beam Therapeutics | Downgrades: Neutral | $35 | $22.57 | +55.07% | 2 | Dec 15, 2023 | |
| TVTX Travere Therapeutics | Maintains: Buy | $41 → $27 | $8.09 | +233.75% | 2 | Sep 22, 2023 | |
| KROS Keros Therapeutics | Initiates: Buy | $65 | $42.81 | +51.83% | 1 | Jul 26, 2023 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $89 → $91 | $22.15 | +310.84% | 2 | Jun 13, 2023 | |
| STOK Stoke Therapeutics | Upgrades: Neutral | $9 → $12 | $12.83 | -6.47% | 3 | May 1, 2023 | |
| SGMO Sangamo Therapeutics | Downgrades: Underperform | $5 → $1.5 | $0.32 | +368.60% | 1 | Apr 28, 2023 | |
| MLYS Mineralys Therapeutics | Initiates: Buy | $39 | $12.09 | +222.58% | 1 | Mar 7, 2023 | |
| RCKT Rocket Pharmaceuticals | Maintains: Buy | $38 → $35 | $19.78 | +76.95% | 2 | Dec 23, 2022 | |
| EDIT Editas Medicine | Maintains: Neutral | $18 → $15 | $4.54 | +230.40% | 2 | Nov 18, 2022 | |
| OMER Omeros | Downgrades: Underperform | $3 | $3.85 | -22.08% | 1 | Nov 8, 2022 | |
| SNTI Senti Biosciences | Initiates: Buy | $7 | $0.39 | +1,694.87% | 1 | Sep 29, 2022 | |
| RDUS Radius Health | Upgrades: Neutral | $8 | $14.67 | -45.47% | 1 | Jun 8, 2022 | |
| S SentinelOne | Maintains: Buy | $67 → $54 | $20.46 | +163.93% | 1 | Mar 16, 2022 | |
| NKTR Nektar Therapeutics | Downgrades: Underperform | $18 → $6 | $1.17 | +412.82% | 2 | Mar 14, 2022 | |
| AGIO Agios Pharmaceuticals | Initiates: Buy | n/a | $42.05 | - | 1 | Dec 3, 2021 |
Liquidia
Dec 21, 2023
Maintains: Buy
Price Target: $13 → $15
Current: $11.83
Upside: +26.80%
Beam Therapeutics
Dec 15, 2023
Downgrades: Neutral
Price Target: $35
Current: $22.57
Upside: +55.07%
Travere Therapeutics
Sep 22, 2023
Maintains: Buy
Price Target: $41 → $27
Current: $8.09
Upside: +233.75%
Keros Therapeutics
Jul 26, 2023
Initiates: Buy
Price Target: $65
Current: $42.81
Upside: +51.83%
Intellia Therapeutics
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $22.15
Upside: +310.84%
Stoke Therapeutics
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $12.83
Upside: -6.47%
Sangamo Therapeutics
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.32
Upside: +368.60%
Mineralys Therapeutics
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $12.09
Upside: +222.58%
Rocket Pharmaceuticals
Dec 23, 2022
Maintains: Buy
Price Target: $38 → $35
Current: $19.78
Upside: +76.95%
Editas Medicine
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $4.54
Upside: +230.40%
Omeros
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $3.85
Upside: -22.08%
Senti Biosciences
Sep 29, 2022
Initiates: Buy
Price Target: $7
Current: $0.39
Upside: +1,694.87%
Radius Health
Jun 8, 2022
Upgrades: Neutral
Price Target: $8
Current: $14.67
Upside: -45.47%
SentinelOne
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $20.46
Upside: +163.93%
Nektar Therapeutics
Mar 14, 2022
Downgrades: Underperform
Price Target: $18 → $6
Current: $1.17
Upside: +412.82%
Agios Pharmaceuticals
Dec 3, 2021
Initiates: Buy
Price Target: n/a
Current: $42.05
Upside: -